Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - The New England Journal of Medicine - 2019

Brief Summary:

Among individuals with HFrEF (NYHA II-IV, LVEF ≤40%) with or without T2DM, the addition of the SGLT-2 inhibitor dapagliflozin decreased rates of CV death or worsening HF, as well as all-cause mortality.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/31535829